Tag: copy

Rogers customers can win tickets to the July 1 game at three surprise GTA locations and on social media on June 30

CALGARY, Alberta and BOGOTÁ, Colombia, June 26, 2026 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. ("Canacol" or the "Company") (TSX: CNE), a leading natural gas exploration and production company operating in Colombia, today announced that the Court of King's Bench of Alberta issued a decision on June 24, 2026, granting Canacol permission to disclaim natural gas supply and transportation contracts as part of its ongoing restructuring under the Companies' Creditors Arrangement Act (CCAA).

Locomotives Arrive in Cameroon

Generated Record Operating Cash Flow of $54.1 Million; Maintained Profitability 

BEIJING, June 25, 2026 (GLOBE NEWSWIRE) -- DSC Holdings Ltd. (“DSC” or the “Company”) (NASDAQ: DSC), the AI application infrastructure for China’s used car industry, today announced that it has priced its initial public offering of 3,000,000 American depositary shares (“ADSs”) at US$17 per ADS, for a total offering size of approximately US$51 million, assuming the underwriters do not exercise their over-allotment option to purchase additional ADSs. Each ADS represents 20 Class A ordinary shares of the Company. The ADSs are expected to begin trading on the Nasdaq Global Market today under the ticker symbol “DSC.” The offering is expected to close on June 26, 2026, subject to customary closing conditions.

TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce today that its wholly owned U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), has entered into a binding memorandum of understanding (the “MOU”) setting out the principal commercial terms for a proposed definitive distribution agreement (the “Definitive Agreement”) with ExoLyra LLC, which operates as an arm’s length third party (“ExoLyra”).

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the “Common Shares”) at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the “Offering”).